Bausch + Lomb Launches Preservative-Free Blink Triple Care

Why It Matters

Removing preservatives addresses safety concerns for chronic users and expands Bausch + Lomb’s reach in the growing dry‑eye market, offering clinicians a longer‑lasting, irritation‑free option.

Key Takeaways

• Preservative‑free Blink Triple Care launches June 2026
• Same active ingredients, no sodium chlorite preservative
• Provides up to 10 hours symptom relief in home study
• Targets evaporative and mixed‑mechanism dry‑eye patients

Pulse Analysis

The dry‑eye market, valued at over $4 billion globally, has been driven by rising screen time, aging populations, and increased awareness of ocular health. Traditional over‑the‑counter artificial tears often contain preservatives like sodium chlorite, which can cause irritation with frequent use. Bausch + Lomb’s decision to release a preservative‑free version of its flagship Blink Triple Care aligns with a broader industry shift toward gentler, long‑term therapies that meet the needs of patients who apply drops multiple times daily.

Blink Triple Care Preservative‑Free maintains the original’s 0.25 % polyethylene glycol 400 base, complemented by polyoxyl‑40 hydrogenated castor oil and sodium hyaluronate, creating a lipid nano‑emulsion that both hydrates and reduces tear evaporation. In a recent in‑home study, users reported up to ten hours of symptom relief, a notable improvement over many OTC options that typically last three to four hours. Ophthalmologists like Dr. Jessilin Quint highlight the formulation’s suitability for individuals with meibomian gland dysfunction or those exposed to climate‑controlled environments, where preserving existing moisture is as critical as adding new hydration.

The launch positions Bausch + Lomb to capture a larger share of the premium dry‑eye segment, competing with brands such as Alcon’s Refresh Preservative‑Free and Novartis’s Systane Ultra. As insurers increasingly cover preservative‑free products and clinicians prioritize patient comfort, demand for longer‑acting, irritation‑free drops is expected to rise. Bausch + Lomb’s move may also spur further innovation, prompting rivals to enhance lipid‑based delivery systems and invest in real‑world effectiveness studies, ultimately expanding therapeutic options for millions of dry‑eye sufferers.